Krystal Biotech Q4 revenue $91.1M (+116% YoY); net income $45.5M; FY revenue $290.5M

Krystal Biotech, Inc.

2024-FY EPS reported $3.00 revenue$290,515,000

Q4 2024 product revenue $91.1M (+116% YoY); full year $290.5M (+473% vs 2023).
Q4 2024 net income $45.5M ($1.58 basic EPS) vs $8.7M ($0.31) in Q4 2023.
Cash, cash eq & investments $749.6M as of Dec 31, 2024.
Pipeline: KB707 solid tumors ORR 27%; KB408 AATD interim positive; CFF sanctioned KB407 CF study.
FY2025 non-GAAP R&D+SG&A guidance $150-175M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.